PerpEquities

Equity · Healthcare

Elevance Health (ELV) perpetual futures

ELV perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade ELVUSDT.

Elevance Health Inc. is a major health benefits organization guiding consumers, families, and communities through healthcare, serving about 118 million individuals with medical, digital, and other solutions.

$433.96+4.9%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · MEXC (ELV/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/2 live markets
Venues
2
Live markets
1/2
24h volume
$99.9K
Open interest
$41.1K
Best liquidity
$3.8K
MEXC
Tightest spread
+56.2 bps
MEXC
Highest volume
$99.9K
MEXC
Settlement mix
USDT · 2/2
Perp/spot vol.
0.00x
Spot volume $750.4M
OI / float
0.00%
Float $93.5B
Spot performance
1D+4.94%
5D+2.16%
1M+12.36%
6M+16.75%
YTD+23.86%
1Y+37.13%

Venue matrix

2 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeELV/USDTTrading$433.96+14.3% APR
+0.013% every 8h
+56.2 bps$3.8K$99.9K$41.1KUSDT20x
BingXTradeELV-USDTWatchlist------USDT-

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 1 venues absorb $10k

Too thin: MEXC

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

ELV

Tightest spread

ELV

Highest volume

ELV

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-10-21 · next report 2027-01-27 · Updated 265h ago
All financials →

Valuation & key figures

Market cap
$95.4B
Updated 265h ago
Revenue
$201.8B
Trailing 12 months
Revenue growth
0%
Next fiscal year
Profit margin
+2.5%
P/E
18.7
Peer P/E 23.8
P/S
0.5
Peer P/E
23.8
Similar listed perps
Free cash flow
$6.5B
Trailing 12 months
Net income
$5.1B
Trailing 12 months
Revenue estimate
$199.8B
Next fiscal year
Earnings
2027-01-27
Revenue est. $49.3B · Updated 265h ago
Dividend
$1.72
2026-12-04
Revenue (TTM)$202B+3.6% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)3.7%-0.7 pp vs a year agoOperating income $7.46B
Net income (TTM)$5.14B-7.1% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$6.51B+72.9% vs a year agoCapex $1.08B
Diluted EPS (TTM)$23.45-4.1% vs a year agoSum of the last 4 quarters
Net cash$7.09B+130.3% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-21): revenue beat by 2.4%, EPS beat by 48.4%Revenue $50.4B vs $49.3B expected (+2.4%); EPS $6.99 vs $4.71 (+48.4%).
  • Revenue growth slowing: 1.4% year on yearQ3 '26 revenue $51.4B, against an average of 6.5% over the four quarters before.
  • Operating margin 3.7% (TTM), -0.7 pp on a year agoOperating income grew -12.0% while revenue grew 3.6%.
  • 19.3% of pre-tax profit is eaten by non-operating lossesPre-tax income $6.25B vs operating income $7.46B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Segments in Q3 '26

from the filing
SegmentRevenuey/yOp. incomeMargin
Reportable Segments$51.4B+1.4%$1.27B2.5%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 395 lines Elevance Health Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-01-27
Revenue est. $49.3B · Updated 265h ago
Dividend
$1.72
2026-12-04

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202628.88$199.8B0%12
FY 202730.19$204.7B+3%12
FY 202834.60$213B+7%5
FY 202939.95$215.3B+8%1
FY 203046.21$234.5B+18%1
Q1 202712.38$50.5B+1%10

Company events

6
2027-01-27EarningsActual - / Estimate 2.1-
2026-12-04Dividend$1.72-
2026-10-21Earnings · Before market openActual 6.99 / Estimate 4.71Beat
2026-09-10Dividend$1.72-
2026-07-15EarningsActual 7.45 / Estimate 6.21Beat
2026-06-10Dividend$1.72-

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 2, 2026, 03:11 PM UTC

Company profile

Sector
Healthcare
Industry
Medical - Healthcare Plans
Chief executive
Gail Koziara Boudreaux
Employees
96,615
IPO date
Oct 30, 2001
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei3.04
Piotroski scorei7/9
Overall ratingiA-
Owner earningsi$1.02B$4.70 per share
ESG risk ratingiB-Industry rank: 15 out of 15

Rating factors

Return on equityi
4
Return on assetsi
4
Debt to equityi
1
Price to earningsi
3
Price to booki
3
Market cap history
$91.41B+9.6%Aug 26 – Oct 26
$83.41B$88.63B$93.86BHigh: $93.86B · 2026-10-26Low: $83.41B · 2026-08-03Latest: $91.41B · 2026-10-30Aug 26Sep 26Oct 26
Latest: $91.41B · 2026-10-30High: $93.86B · 2026-10-26Low: $83.41B · 2026-08-03
Largest fund holders
FundWeightShares held
VCPA.S0.35%16.6M
VTI0.11%6.7M
VSCA.S0.22%6.7M
VOO0.12%5.5M
VWNAX1.73%3M
IVV0.14%2.9M
XSP.TO0.14%2.9M
SPY0.14%2.6M
VEIPX1.22%2M
VTV0.31%2M
VGHAX1.79%1.8M
XLV1.37%1.6M

Analyst track record

How the analysts covering ELV have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings120333
Analysts2226
Buy / hold / sell90 / 30 / 0281 / 52 / 0
Upgrades / downgrades / initiations4 / 2 / 15 / 8 / 8
Price targets hit / missed61 / 55 (53%)109 / 206 (35%)
Avg. return after a rating (TipRanks)+1.0%-7.0%
Best / worst call+31.9% / -19.3%+42.1% / -35.6%

After buy calls on this stock: median 21-day move +0.2% vs S&P 500 -2.1% (n = 284)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Stephen BaxterWells Fargo50% hit rate on this stock · 28 targets measuredBuytarget $492Oct 27, 2026
  2. Ryan LangstonTD Cowen45% hit rate on this stock · 11 targets measuredBuytarget $495Oct 23, 2026
  3. Sarah JamesCantor Fitzgerald36% hit rate on this stock · 14 targets measuredBuytarget $450Jul 7, 2026

Latest ratings

DateAnalystCallTarget
Oct 27, 2026Stephen BaxterWells FargoBuyReiterated$492
Oct 23, 2026Ryan LangstonTD CowenBuyMaintained$495
Oct 23, 2026Ann HynesMizuho SecuritiesBuyMaintained$490
Oct 22, 2026Scott FidelGoldman SachsHoldMaintained$451
Oct 23, 2026Ryan LangstonTD CowenBuyMaintained$495
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$280$300$320$340$360$380$400$420$440Dec 25 · Buy 12 · Hold 7 · Sell 0Dec 25Jan 26 · Buy 12 · Hold 5 · Sell 0Feb 26 · Buy 11 · Hold 5 · Sell 0Feb 26Mar 26 · Buy 11 · Hold 5 · Sell 0Apr 26 · Buy 13 · Hold 7 · Sell 0Apr 26May 26 · Buy 15 · Hold 5 · Sell 0Jun 26 · Buy 15 · Hold 5 · Sell 0Jun 26Jul 26 · Buy 14 · Hold 6 · Sell 0Aug 26 · Buy 14 · Hold 7 · Sell 0Aug 26Sep 26 · Buy 14 · Hold 7 · Sell 0Oct 26 · Buy 14 · Hold 7 · Sell 0Oct 26Nov 26 · Buy 14 · Hold 7 · Sell 0Dec 25 · avg. target $382Jan 26 · avg. target $390Feb 26 · avg. target $386Mar 26 · avg. target $381Apr 26 · avg. target $385May 26 · avg. target $400Jun 26 · avg. target $415Jul 26 · avg. target $445Aug 26 · avg. target $445Sep 26 · avg. target $446Oct 26 · avg. target $465Nov 26 · avg. target $465Dec 25 · month-end close $351Jan 26 · month-end close $346Feb 26 · month-end close $320Mar 26 · month-end close $293Apr 26 · month-end close $376May 26 · month-end close $393Jun 26 · month-end close $387Jul 26 · month-end close $376Aug 26 · month-end close $393Sep 26 · month-end close $389Oct 26 · month-end close $420Nov 26 · month-end close $420

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Oct 30, 2026 · 120 ratings

Frequently asked questions

Where can I trade ELV perpetual futures?

Elevance Health (ELV) perpetual futures trade on 1 crypto venues, including MEXC. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade ELV around the clock?

Yes. Unlike the underlying stock, ELV perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on ELV perpetuals?

Right now the ELV perp funding rate is +14.3% annualized (venue median), ranging from +14.3% to +14.3% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the ELV perp price compare to the Elevance Health stock?

The venue-median ELV perp mark is $434 versus a reference stock price of $434, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a ELV perpetual future?

A ELV perpetual is a derivative that tracks the price of Elevance Health with no expiry date. It lets you take long or short exposure to Elevance Health on crypto venues, around the clock.

What is ELVUSDT perpetual?

ELVUSDT is the symbol most crypto exchanges use for the Elevance Health perpetual settled in USDT (Tether). It tracks the ELV share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

ELV perpetuals · perpequities.comELV perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/elv-perp"><img src="https://perpequities.com/badge/elv-perp.svg" width="240" height="64" alt="ELV perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of ELV perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for ELV — one email every Sunday.

Watchlist and alerts

Price and funding alerts for ELV, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X